
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.900
Open
11.760
VWAP
11.79
Vol
8.68M
Mkt Cap
6.52B
Low
11.660
Amount
102.41M
EV/EBITDA(TTM)
--
Total Shares
572.78M
EV
4.77B
EV/OCF(TTM)
14.88
P/S(TTM)
4.54
UiPath, Inc. is an enterprise automation and artificial intelligence (AI) software company. The Company is principally focused on building and managing automations and developing computer vision technology. The Company provides its customers with a set of capabilities that allow them to discover opportunities for automation, automate using a digital workforce that seamlessly collaborates with humans, and operate a mission-critical automation program at scale. It enables employees to build automations for both existing and new processes and to automate a range of actions including logging into applications, extracting information from documents, moving folders, filling in forms, reading emails, and updating information fields and databases. Its platform allows users to design and combine UI automations, API integrations, and AI-based document understanding in a single workflow. It offers a managed, multi-tenant software as a service (SaaS) version and automation cloud.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2026Q2
FY2026Q3
332.17M
-0.88%
0.102
-21.56%
331.43M
+4.8%
0.069
+71.75%
389.48M
+9.82%
0.128
+16.13%
Estimates Revision
The market is revising Downward the revenue expectations for UiPath Inc. (PATH) for FY2026, with the revenue forecasts being adjusted by -3.87% over the past three months. During the same period, the stock price has changed by -18.93%.
Revenue Estimates for FY2026
Revise Downward

-3.87%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward

+6.22%
In Past 3 Month
Stock Price
Go Down

-18.93%
In Past 3 Month
21 Analyst Rating

1.27% Upside
Wall Street analysts forecast PATH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PATH is 11.97 USD with a low forecast of 10.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
16 Hold
2 Sell
Hold

1.27% Upside
Current: 11.820

Low
10.00
Averages
11.97
High
15.00

1.27% Upside
Current: 11.820

Low
10.00
Averages
11.97
High
15.00
Mizuho
Siti Panigrahi
Hold
Maintains
$12 → $11
2025-04-15
Reason
Mizuho
Siti Panigrahi
Price Target
$12 → $11
2025-04-15
Maintains
Hold
Reason
Mizuho lowered the firm's price target on UiPath to $11 from $12 and keeps a Neutral rating on the shares as part of a Q1 preview for the software sector. The firm cut price targets across the group to reflect recent software multiple compression. However, the recent selloff presents an "attractive buying opportunity," the analyst tells investors in a research note. Mizuho expects strong Q1 reports but cautious management tones on the fiscal year. Tariffs are "unlikely to shake" core software-as-a-service fundamentals," the analyst tells investors in a research note.
Needham
Scott Berg
Hold
Reiterates
n/a
2025-03-26
Reason
Needham
Scott Berg
Price Target
n/a
2025-03-26
Reiterates
Hold
Reason
RBC Capital
Matthew Hedberg
Hold
Reiterates
$13
2025-03-26
Reason
RBC Capital
Matthew Hedberg
Price Target
$13
2025-03-26
Reiterates
Hold
Reason
BMO Capital
Keith Bachman
Hold
Maintains
$16 → $12
2025-03-14
Reason
BMO Capital
Keith Bachman
Price Target
$16 → $12
2025-03-14
Maintains
Hold
Reason
BMO Capital lowered the firm's price target on UiPath to $11.50 from $16 and keeps a Market Perform rating on the shares. The company had a lackluster quarter, missing reported ARR an revenue estimates, and provided "disappointing" FY26 guidance that is back-end weighted, the analyst tells investors in a research note. The firm, whose FY26 ARR and revenue estimates are both moving lower, said it has concerns about UiPath's durable growth rate given growth of various agentic solutions, competitive landscape, and a challenging macro environment including the risk in the public sector, which is the company's third largest vertical.
B of A Securities
Brad Sills
Hold
to
Sell
Downgrades
$18 → $10
2025-03-13
Reason
B of A Securities
Brad Sills
Price Target
$18 → $10
2025-03-13
Downgrades
Hold
to
Sell
Reason
Needham
Scott Berg
Hold
Reiterates
n/a
2025-03-13
Reason
Needham
Scott Berg
Price Target
n/a
2025-03-13
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for UiPath Inc (PATH.N) is 21.84, compared to its 5-year average forward P/E of 130.44. For a more detailed relative valuation and DCF analysis to assess UiPath Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
130.44
Current PE
21.84
Overvalued PE
1153.40
Undervalued PE
-892.52
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-172.24
Current EV/EBITDA
16.61
Overvalued EV/EBITDA
565.96
Undervalued EV/EBITDA
-910.44
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
11.80
Current PS
4.20
Overvalued PS
21.99
Undervalued PS
1.60
Financials
Annual
Quarterly
FY2025Q4
YoY :
+4.54%
423.65M
Total Revenue
FY2025Q4
YoY :
+182.86%
42.68M
Operating Profit
FY2025Q4
YoY :
+52.71%
51.79M
Net Income after Tax
FY2025Q4
YoY :
+50.00%
0.09
EPS - Diluted
FY2025Q4
YoY :
-2.21%
138.69M
Free Cash Flow
FY2025Q4
YoY :
-1.73%
85.34
Gross Profit Margin - %
FY2025Q4
YoY :
-4.13%
21.38
FCF Margin - %
FY2025Q4
YoY :
+46.12%
12.23
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
127.3K
USD
1
3-6
Months
1.3M
USD
3
6-9
Months
873.1K
USD
2
0-12
Months
1.1M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
8.4M
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
3
3.6M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
8
7.2M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
127.3K
USD
1
3-6
Months
1.3M
USD
3
6-9
Months
873.1K
USD
2
0-12
Months
1.1M
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PATH News & Events
Events Timeline
2025-04-24 (ET)
2025-04-24
06:24:04
Redis and UiPath expand existing collaboration

2025-04-09 (ET)
2025-04-09
11:03:15
UiPath announces AI partnership with Google Cloud

2025-03-13 (ET)
2025-03-13
12:00:48
UiPath falls -14.9%

Sign Up For More Events
Sign Up For More Events
News
5.0
04-26BenzingaCathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms
7.5
04-24NewsfilterRedis and UiPath Build on Existing Collaboration to Deliver Agentic Automation to Enterprises via On-Premises Solutions
5.0
04-24BenzingaCathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs
Sign Up For More News
People Also Watch

PROK
ProKidney Corp
1.080
USD
+4.85%

ALRS
Alerus Financial Corp
20.120
USD
+13.29%

GLRE
Greenlight Capital Re Ltd
13.230
USD
+0.68%

RDVT
Red Violet Inc
39.320
USD
+4.35%

SVRA
Savara Inc
3.260
USD
+2.19%

PFIS
Peoples Financial Services Corp
43.710
USD
+1.44%

STOK
Stoke Therapeutics Inc
9.510
USD
+0.42%

ANGO
AngioDynamics Inc
9.580
USD
+0.63%

ALT
Altimmune Inc
5.100
USD
+0.79%

IVR
Invesco Mortgage Capital Inc
7.470
USD
+0.95%
FAQ

What is UiPath Inc (PATH) stock price today?
The current price of PATH is 11.82 USD — it has increased 1.9 % in the last trading day.

What is UiPath Inc (PATH)'s business?

What is the price predicton of PATH Stock?

What is UiPath Inc (PATH)'s revenue for the last quarter?

What is UiPath Inc (PATH)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for UiPath Inc (PATH)'s fundamentals?

How many employees does UiPath Inc (PATH). have?
